SLAMF7 and neoplasm: In this study, MSCs were used as carriers for a cell therapy strategy, utilizing their tumor‐homing characteristics that respond to TGF‐β to achieve controlled release of bioactive proteins (IL‐12 or nCD47‐SLAMF7) in the tumor microenvironment while avoiding systemic toxicity.